IMDX · Insight Molecular Diagnostics Inc.
$4.32
+0.61 (+16.44%)
At close · Aug 14
Going-concern doubt
— cleared Aug 10, 2026
The latest filing states the doubt was alleviated.
“Our expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that the consolidated financial statements are issued. ... Management has concluded that it is probable that our plans will be effectively implemented and that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about our ability to continue as a going concern within one year after the date of issuance of these consolidated financial statements. ... Accordingly, management has concluded that substantial doubt does not exist about the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements.”View the 10-Q filed Aug 10, 2026
Market Cap
$141.37M
Shares
32.72M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.32
Open$3.76
Day$3.76–4.36
52W close$2.40–8.48
Avg vol 30d232K
Short int1.1M · 3.3% float · 11.1d
Short vol57%
Last earningsAug 10, 2026
DataJul 2023–Aug 2026
Filing10-Q · Aug 10
Raw chart and full-history price indicators begin at the captured split on Jul 25, 2023; bars on opposite sides are not compared.
Up next
Next earnings call
Nov 8, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 10, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−20%
below
Price vs 50-day avg
−15%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
32%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−9%
trailing
6-month return
−24%
trailing
YTD return
−42%
this year
Relative strength
−38%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow
Distributing
-2% holders QoQ · +12 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.28% of float · ▼ -13.8% MoM · 11.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
40 holders — near 3-yr high, broad support
Squeeze score
55
elevated · 0–100
Fundamentals
EPS growth
+65%
Y/Y
Free cash flow
$-25.4M
Balance sheet
$9.7M
net cash
Quant / Vol
risk profile
Volatility
109%
annualized · 1-yr
Max drawdown
−70%
past year
ATR
10.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−20%
Bearish
Price vs 50-day avg
−15%
Bearish
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
32%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow
Distributing
-2% holders QoQ · +12 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.28% of float · ▼ -13.8% MoM · 11.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
40 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $4 · 32%
Range high $8
vs 200-day avg -20%
vs 50-day avg -15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| U.S. transplant centers expressed interest in being part of our registry | 34 | Q1 2026 | — |
| International transplant centers engaged | 11 | as of March 2026 (referenced in Q4 2025 results) | — |
| U.S. transplant centers engaged | 37 | as of March 2026 (referenced in Q4 2025 results) | — |
| U.S. transplant centers interested in joining registry trial | 28 | as of March 2026 (referenced in Q4 2025 results) | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IMDX
this stock
Insight Molecular Diagnostics Inc.
|
$141.37M | -42.4% | +115.6% | — | 3.3% |
|
TMO
Thermo Fisher Scientific Inc.
|
$217.52B | +1.5% | +14.5% | 31.7 | 1.3% |
|
DHR
Danaher Corp /De/
|
$142.32B | -11.6% | +8.5% | 35.9 | 1.7% |
|
NTRA
Natera, Inc.
|
$44.67B | +35.3% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$43.41B | -18.6% | +10.4% | 38.7 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Jul 25, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IMDX | -10.6% | -8.9% | -24.1% | -7.1% | -42.4% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -11.0% | -13.3% | -37.9% | -11.0% | -56.3% |
Key facts
CIK
1642380
CUSIP
68235C206
13F (30d)
37 filings
37 filers
Visit website
Investor relations